Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2

@article{Lee2018PreclinicalPI,
  title={Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2},
  author={W. Lee and S. R. Shim and Seon Young Lee and J. S. Yoo and S. Cho},
  journal={Drug Design, Development and Therapy},
  year={2018},
  volume={12},
  pages={495 - 504}
}
Background VEGF is a highly selective mitogen that serves as the central regulator of tumor angiogenesis by mediating endothelial proliferation, permeability, and survival. Tanibirumab (TTAC-0001) is a fully human IgG1 monoclonal antibody derived from a fully human naïve single-chain variable fragment (ScFv) phage library that was developed to inhibit the effects of VEGF in the treatment of solid tumors, especially those of the brain. Methods In the present study, we conducted intravenous… Expand
4 Citations

References

SHOWING 1-10 OF 23 REFERENCES
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
  • Y. Lin, C. Nguyen, +4 authors N. Modi
  • Biology, Medicine
  • The Journal of pharmacology and experimental therapeutics
  • 1999
Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins
Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)
  • S. Lee
  • Medicine, Chemistry
  • Archives of pharmacal research
  • 2011
The allometric approach for interspecies scaling of pharmacokinetic parameters.
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
  • H. Boxenbaum
  • Biology, Medicine
  • Journal of Pharmacokinetics and Biopharmaceutics
  • 2005
...
1
2
3
...